Bioelectronics company Thync touted positive results today from the pilot study of its neuromodulation technology as a treatment for plaque psoriasis.
The study showed that people using Thync’s technology experienced reduced redness, scaling and itchiness of their plaque psoriasis after four weeks, according to the Los Gatos, Calif.-based company.
As part of the study, people used Thync’s neuromodulation technology for at least 10 minutes each day for four weeks. Both the treatment and control groups included people with mild to severe psoriasis, an autoimmune skin disorder without a cure or vaccine.
